DR. Stefan Backx SRL

DR. Stefan Backx reported total assets of €1.22m at the end of the 2025 financial year (annual accounts filed with the NBB on 05 Nov 2026).

Company number (CBE) 0472.295.275 · VAT BE0472295275
2800 Mechelen
active in Research and experimental development on biotechnology (NACE 72101)
operating since 05 Jul 2000 (≈ 26 yrs)
Public Public page: latest year only. The score, history and details open with a free account. Create a free account
Idonis solidity score
EDCBA

The score of DR. Stefan Backx shows with a free account.

See the score
Profile
SRL since 2000
Components
  • Summary? / 5
    • Balance sheet strength
    • Liquidity
    • Repayment capacity
    • Profitability
    • Trajectory
    • Compliance and register
  • Position in its sectorvs peers
  • Supplier creditat 30 d
  • Borrowing capacityborrowable
  • Valuationcentral

Visible once signed in: create your account, the 14-day Pro trial is free.

Detail

Key figures 2025

Net result22,933 €
Equity€1.18m
Cash153,087 €
EBITDA33,180 €
Total assets€1.22m
Solvency97.1%
The line marks its sector median: 60.4% (425 companies).

Change 2022 → 2025: Equity +44 % Total assets +25 %

Accounts of the company itself (not consolidated).

The full file covers 9 financial years; a free account shows 2. →

Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error

DR. Stefan Backx's annual accounts

20252024202320222021
Net result22,933 €
Equity€1.18m
Cash153,087 €
EBITDA33,180 €
Total assets€1.22m

Filed annual accounts

  • Year ended 31 Dec 2025filed on 05 Nov 2026
  • Year ended 31 Dec 2024filed on 30 Jul 2025
  • Year ended 31 Dec 2023filed on 27 Aug 2024
  • Year ended 31 Dec 2022filed on 27 Nov 2023
  • Year ended 31 Dec 2021filed on 13 Oct 2022

DR. Stefan Backx's financial analysis

Management and control of DR. Stefan Backx

1 active director(s) in the register.

DR. Stefan Backx's shareholders and holdings →

DR. Stefan Backx's publications in the Belgian Gazette

Company number, VAT number and registered office

Company number (CBE)
0472.295.275
VAT number
BE0472295275
Peppol
Not found on Peppol as of 10 Nov 2026 · Check
Legal form
SRL
Incorporated
05 Jul 2000
Registered office
2800 Mechelen
Latest accounts
2025 · filed on 05 Nov 2026
Activity
Research and experimental development on biotechnology (NACE 72101)

DR. Stefan Backx (SRL) has been based in Mechelen since 2000, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 22,933 € and equity of €1.18m; its revenue is not published. Its solvency stands at 97.1%, above the median of its sector (60.4%).

Companies similar to DR. Stefan Backx

Companies in the same business, of comparable size and area, outside its group.

Frequently asked questions about DR. Stefan Backx

What is the revenue of DR. Stefan Backx?

DR. Stefan Backx files its accounts in a format where revenue is optional: it is not published for 2025.

What is the VAT number of DR. Stefan Backx?

In Belgium, the VAT number is the company number prefixed with BE: BE0472295275 for DR. Stefan Backx, if the company is VAT-registered. Its company number (CBE) is 0472.295.275.

Where is the registered office of DR. Stefan Backx?

According to the CBE register, the registered office of DR. Stefan Backx is in 2800 Mechelen.

What is the equity of DR. Stefan Backx?

At the close of the 2025 financial year, the equity of DR. Stefan Backx amounts to 1,181,850 €, a solvency of 97.1% of total assets.

Who manages DR. Stefan Backx?

The register lists 1 active mandates at DR. Stefan Backx. Names and roles are in the full file, with the deeds published in the Belgian Gazette.

Idonis

The full file of DR. Stefan Backx

Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.

Open the full file →
Free account in 30 seconds, by email. No bank card.
Sources : Annual accounts — NBB ↗ Register — CBE ↗ Deeds — Belgian Gazette ↗ · Updated on 11 Nov 2026

No credit card, no commitment.

What each plan unlocks →